Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA cancels meeting on J&J’s ceftobiprole

Executive Summary

FDA cancels the Anti-Infective Drugs Advisory Committee meeting scheduled for Feb. 28 to discuss Johnson & Johnson's NDA for the broad-spectrum cephalosporin antibiotic ceftobiprole. The committee will still meet on Feb. 27 to discuss Theravance's telavancin for the treatment of complicated skin and skin structure infection (1"The Pink Sheet," Jan. 14, 2008, In Brief)...

You may also be interested in...

Advisory committee to review two antibiotics

The Anti-Infective Drugs Advisory Committee will review Johnson & Johnson's ceftobiprole medocaril Feb. 27, and Theravance/Astella's telavancin Feb. 28. Committee discussion may center on the use of non-inferiority studies to support the applications for the treatment of complicated skin and skin structure infections; such designs are discouraged by draft FDA guidance, and the agency may want reassurance on efficacy questions (1"The Pink Sheet" Oct. 22, 2007, p. 17)...

QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.

Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts